TMPRSS2 and COVID-19: Of these, the estrogen-related compounds (estradiol and genistein) and the androgen receptor antagonist (enzalutamide) block TMPRSS2 [177,178,179], which is required for SARS-CoV-2 spike protein priming and appear to be the most promising repurposing candidates for symptom amelioration in COVID-19 patients.